3-51629381-A-G
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 4 ACMG points: 4P and 0B. PM2PP3PP5
The NM_015106.4(RAD54L2):c.389A>G(p.Gln130Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (no stars).
Frequency
Genomes: not found (cov: 32)
Consequence
RAD54L2
NM_015106.4 missense
NM_015106.4 missense
Scores
6
10
3
Clinical Significance
Conservation
PhyloP100: 8.95
Genes affected
RAD54L2 (HGNC:29123): (RAD54 like 2) Predicted to enable ATP hydrolysis activity; protein kinase binding activity; and transcription coregulator activity. Predicted to be involved in DNA duplex unwinding. Predicted to act upstream of or within positive regulation of transcription by RNA polymerase II. Predicted to be located in nuclear speck. Predicted to be active in nucleus. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 4 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.749
PP5
Variant 3-51629381-A-G is Pathogenic according to our data. Variant chr3-51629381-A-G is described in ClinVar as [Likely_pathogenic]. Clinvar id is 3374700.Status of the report is no_assertion_criteria_provided, 0 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RAD54L2 | NM_015106.4 | c.389A>G | p.Gln130Arg | missense_variant | 5/23 | ENST00000684192.1 | NP_055921.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RAD54L2 | ENST00000684192.1 | c.389A>G | p.Gln130Arg | missense_variant | 5/23 | NM_015106.4 | ENSP00000507587.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 genomes
Cov.:
32
GnomAD4 exome Cov.: 30
GnomAD4 exome
Cov.:
30
GnomAD4 genome Cov.: 32
GnomAD4 genome
Cov.:
32
ClinVar
Significance: Likely pathogenic
Submissions summary: Pathogenic:1
Revision: no assertion criteria provided
LINK: link
Submissions by phenotype
TOP2 deficiency type 1 Pathogenic:1
Likely pathogenic, no assertion criteria provided | clinical testing;in vitro | University Medical Center Utrecht, University Utrecht | - | De novo variant in RAD54L2 that is absent in father/mother of the individual (trio Whole Exome Sequencing). Predicted as disease-causing by multiple lines of computational evidence. MutationTaster: disease causing (probability 0.99). Cadd score: 25.7. Low tolerance against loss-of-function (pLI=1). Highly conserved region of the protein, including Gln130 (Phastcons=1, PhyloP=4.58). Structural information about the variant/impact of the variant cannot be provided as the crystal structure of the N-terminal region of RAD4L2 is not known. We studied DNA damage repair capacity after X-ray irradiation and/or after etoposide treatment, a chemotherapeutic agent that stabilizes DNA topoisomerase II cleavage complexes (TOP2ccs), as RAD54L2 is involved in TOP2cc resolution. (D'Alessandro et al., 2023). RAD54L2 knockout cell lines show increased sensitivity to Etoposide treatment.(D'Alessandro et al., 2023). While survival after X-ray irradiation was not appreciably affected in patient-derived fibroblasts of the individual with RAD54L2 VUS, we observed decreased survival of fibroblasts upon etoposide treatment compared to healthy control cells. In addition, compared to control cells, we observed increased yH2AX foci in patient-derived fibroblasts of the indiviudal with RAD54L2 VUS immediately after etoposide treatment (0 hour), which normalized after 4 and 8 hours. Additionally, we did not observe any changes in yH2AX foci levels in individual 106 upon treatment with ionizing radiations, in agreement to the survival data. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Uncertain
D
BayesDel_noAF
Uncertain
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Uncertain
D
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D
M_CAP
Benign
T
MetaRNN
Pathogenic
D
MetaSVM
Benign
T
MutationAssessor
Uncertain
M
PrimateAI
Pathogenic
T
PROVEAN
Uncertain
D
REVEL
Uncertain
Sift
Uncertain
D
Sift4G
Uncertain
D
Polyphen
D
Vest4
MutPred
Gain of MoRF binding (P = 0.0199);
MVP
MPC
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
No publications associated with this variant yet.